263 related articles for article (PubMed ID: 26446868)
21. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
Liu Q; Zhang H; Fang Q; Qin L
J Clin Exp Neuropsychol; 2017 Nov; 39(9):854-865. PubMed ID: 28052720
[TBL] [Abstract][Full Text] [Related]
22. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
23. Meta-Analysis: Reduced Risk of Anxiety with Psychostimulant Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Coughlin CG; Cohen SC; Mulqueen JM; Ferracioli-Oda E; Stuckelman ZD; Bloch MH
J Child Adolesc Psychopharmacol; 2015 Oct; 25(8):611-7. PubMed ID: 26402485
[TBL] [Abstract][Full Text] [Related]
24. Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis.
Coghill DR; Seth S; Pedroso S; Usala T; Currie J; Gagliano A
Biol Psychiatry; 2014 Oct; 76(8):603-15. PubMed ID: 24231201
[TBL] [Abstract][Full Text] [Related]
25. Recommendation for Long-term Management of Adult Attention-Deficit/Hyperactivity Disorder in Military Populations, Veterans, and Dependents: A Narrative Review.
Baughman DJ; Watson CM; Beich JW; Herboso MNJ; Cuttie LK; Marlyne AC
Mil Med; 2024 May; 189(5-6):e1343-e1352. PubMed ID: 37878798
[TBL] [Abstract][Full Text] [Related]
26. Safety of stimulant treatment in attention deficit hyperactivity disorder: part II.
Merkel RL
Expert Opin Drug Saf; 2010 Nov; 9(6):917-35. PubMed ID: 20615078
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
Biederman J; Swanson JM; Wigal SB; Kratochvil CJ; Boellner SW; Earl CQ; Jiang J; Greenhill L
Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
[TBL] [Abstract][Full Text] [Related]
28. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
29. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
Aman MG; Binder C; Turgay A
J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
[TBL] [Abstract][Full Text] [Related]
30. Treatment Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.
Farhat LC; Flores JM; Avila-Quintero VJ; Polanczyk GV; Cipriani A; Furukawa TA; Bloch MH; Cortese S
JAMA Psychiatry; 2024 Feb; 81(2):157-166. PubMed ID: 37878348
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
[TBL] [Abstract][Full Text] [Related]
32. A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients.
Bushe C; Day K; Reed V; Karlsdotter K; Berggren L; Pitcher A; Televantou F; Haynes V
J Psychopharmacol; 2016 May; 30(5):444-58. PubMed ID: 27005307
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
[TBL] [Abstract][Full Text] [Related]
35. Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis.
Mészáros A; Czobor P; Bálint S; Komlósi S; Simon V; Bitter I
Int J Neuropsychopharmacol; 2009 Sep; 12(8):1137-47. PubMed ID: 19580697
[TBL] [Abstract][Full Text] [Related]
36. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
Gibson AP; Bettinger TL; Patel NC; Crismon ML
Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Adderall for Attention-Deficit/Hyperactivity Disorder: a meta-analysis.
Faraone SV; Biederman J
J Atten Disord; 2002 Sep; 6(2):69-75. PubMed ID: 12142863
[TBL] [Abstract][Full Text] [Related]
38. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
Buitelaar JK; Sobanski E; Stieglitz RD; Dejonckheere J; Waechter S; Schäuble B
J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962
[TBL] [Abstract][Full Text] [Related]
39. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis.
Schachter HM; Pham B; King J; Langford S; Moher D
CMAJ; 2001 Nov; 165(11):1475-88. PubMed ID: 11762571
[TBL] [Abstract][Full Text] [Related]
40. Effect of Continuing and Discontinuing Medications on Quality of Life After Symptomatic Remission in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis.
Tsujii N; Okada T; Usami M; Kuwabara H; Fujita J; Negoro H; Kawamura M; Iida J; Saito T
J Clin Psychiatry; 2020 Mar; 81(3):. PubMed ID: 32237294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
